Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.74 |
| ▸ | DRD3 | P35462 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | DRD2 | P14416 | 2/20 | 0.74 |
| ▸ | HTR2B | P41595 | 2/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.74 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.74 |
| ▸ | HTR3B | O95264 | 1/20 | 0.74 |
| ▸ | MPO | P05164 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | DRD4 | P21917 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.74 |
| ▸ | HTR2C | P28335 | 1/20 | 0.74 |
| ▸ | HTR3A | P46098 | 1/20 | 0.74 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.74 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415869 | 0.87 | ADRA2A (0.63) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| SCHEMBL17068280 | 0.86 | ADRA2A (0.76) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL27855472 | 0.85 | HTR4 (1.00) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL18629 | 0.85 | HTR4 (1.00) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Bromopride SCHEMBL54497 | 0.85 | ADRA2A (1.00) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| SCHEMBL2624889 | 0.85 | ADRA2A (0.74) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL28222039 | 0.85 | HTR4 (1.00) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL10385638 | 0.84 | HTR4 (0.98) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Metoclopramide SCHEMBL8160010 | 0.84 | HTR4 (0.98) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Bromopride SCHEMBL8385045 | 0.84 | ADRA2A (0.98) | ADRA2ACYP2D6DRD3LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197715-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| WO-2024105610-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-7850948-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AG (DE) | 2010-12-14 | — | — | US | disclosed |
| WO-2010028281-A1 | PHARMACEUTICAL COMPOSITION OF A RADIOIODINATED BENZAMIDE DERIVATIVE AND METHODS OF MAKING THE SAME | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20090012090-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2009-01-08 | — | — | US | disclosed |
| US-7427390-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | SCHERING AG (DE) | 2008-09-23 | — | — | US | disclosed |
| EP-1722827-A2 | RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY | Schering AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005089815-A2 | RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY | SCHERING AG (DE) | 2005-09-29 | — | — | WO | disclosed |
| US-20050207972-A1 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197715-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | WRN, RECQL, BLM | ADRA2A 3838/4885CYP2D6 2424/4885DRD3 3952/4885 |
| US-20090012090-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | BRDT, AADAC, IDH2 | ADRA2A 908/4885CYP2D6 373/4885DRD3 1221/4885 |
| US-20050207972-A1 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BRDT, AADAC, IDH2 | ADRA2A 908/4885CYP2D6 373/4885DRD3 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.